Entrada’s proprietary intracellular biologics platform enables the intracellular delivery of biologics to address devastating diseases and transform patients’ lives. This platform can deliver a variety of modalities, allowing for the development of programs across several intracellular target classes.
Intracellular Enzyme Replacement Therapy
Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell. By delivering the enzyme directly into the cell, Entrada can address intracellular enzyme deficiencies in a safe, predictable and controlled manner.
Entrada’s lead program targets a rare, fatal, mitochondrial disease caused by mutations in a gene that codes for an intracellular enzyme. As a result of this defective gene, toxic metabolites accumulate in patients causing significant gastrointestinal and neuromuscular damage.
Protein-Protein Interaction Inhibitors
Intracellular protein-protein interactions (PPIs) is an emerging class of undruggable targets. Targeting intracellular PPIs with PPI inhibitors represents a significant untapped clinical and commercial opportunity for Entrada.
Entrada’s platform technology can also be used to carry other cargos into the cell. We are actively exploring several additional applications beyond our IC-ERT and PPI inhibitor programs.